Therefore it is plausible that KRAS status may also determine whether the surrogate endpoint is in the causal pathway of the disease process, and the extent to which the intervention effect is mediated through the surrogate.This assessment is important clinically, given the large proportion of patients who harbour WT tumours and are therefore eligible for EGFR based therapies. The gene discussed is KRAS; the disease is neoplasm.